Isolation and structure elucidation of Dm-CVNH, a new cyanovirin-N homolog with activity against SARS-CoV-2 and HIV-1.
Saved in:
| Title: | Isolation and structure elucidation of Dm-CVNH, a new cyanovirin-N homolog with activity against SARS-CoV-2 and HIV-1. |
|---|---|
| Authors: | Orfanoudaki M; Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA., Krumpe LRH; Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA., Shenoy SR; Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA., Wilson J; Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA., Guszczynski T; Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA., Henrich CJ; Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA; Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Temme JS; Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA., Gildersleeve JC; Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA., Molina-Molina E; IrsiCaixa, Germans Trias i Pujol Research Institute (IGTP), Universitat Autònoma de Barcelona (UAB), Badalona, Spain., Erkizia I; IrsiCaixa, Germans Trias i Pujol Research Institute (IGTP), Universitat Autònoma de Barcelona (UAB), Badalona, Spain., Blanco J; IrsiCaixa, Germans Trias i Pujol Research Institute (IGTP), Universitat Autònoma de Barcelona (UAB), Badalona, Spain; Department of Infectious Diseases and Immunity, Centre for Health and Social Care Research (CESS), Faculty of Medicine, University of Vic-Central University of Catalonia (UVic-UCC), Vic, Spain; CIBER Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain., Izquierdo-Useros N; IrsiCaixa, Germans Trias i Pujol Research Institute (IGTP), Universitat Autònoma de Barcelona (UAB), Badalona, Spain; CIBER Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain., Montiero F; Embrapa Genetic Resources and Biotechnology National Institute of Science and Technology in Synthetic Biology, Brasília, Brazil., Tanuri A; Embrapa Genetic Resources and Biotechnology National Institute of Science and Technology in Synthetic Biology, Brasília, Brazil., Rech E; Embrapa Genetic Resources and Biotechnology National Institute of Science and Technology in Synthetic Biology, Brasília, Brazil., O'Keefe BR; Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA; Natural Products Branch, Developmental Therapeutic Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, Maryland, USA. Electronic address: okeefeba@mail.nih.gov. |
| Source: | The Journal of biological chemistry [J Biol Chem] 2025 Mar; Vol. 301 (3), pp. 108319. Date of Electronic Publication: 2025 Feb 14. |
| Publication Type: | Journal Article; Research Support, N.I.H., Intramural |
| Journal Info: | Publisher: Elsevier Inc. on behalf of American Society for Biochemistry and Molecular Biology Country of Publication: United States NLM ID: 2985121R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1083-351X (Electronic) Linking ISSN: 00219258 NLM ISO Abbreviation: J Biol Chem Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
